Grant: Operating Grant: COVID-19 Rapid Research Funding Opportunity - Diagnostics
Centre hospitalier de l'Université de Montréal (CHUM)
$0.00
Early immune predictors of sustained SARS-CoV-2 antibody responses after COVID-19 disease
FY 2020-21
Summary
COVID-19, a disease caused by a new Coronavirus, is an unprecedented global health crisis for which we currently have nor safe nor rapid response. Given the absence of vaccines and effective therapies, it is essential to understand the development, effectiveness and maintenance of antiviral responses against its causing agent, the SARS-CoV-2 virus. The highly variable immune response against SARS-CoV-2 define the severity of the disease, but many critical questions remain: 1) can we predict patients that will experience a severe disease and delayed viral clearance? 2) do survivors of COVID-19 develop durable and protective antiviral immunity? 3) can serology identify convalescent COVID-19 patients who are at high risk of re-infection? 4) does re-exposure to the virus boost their antiviral immunity?
We propose the creation of a multi-site consortium composed of 12 scientists (6 women and 6 men) with solid expertise in virology and immunology and from leading academic institutions in Québec (UdeM, IRCM) and the US (Columbia, NY) to study antiviral immunity in COVID-19 in both sexes to address unresolved issues, as outlined in the CIHR call: in Aim 1 and 2, we focus on early clinical and immunological features of COVID-19 that can predict the emergence of protective and durable antibodies. We will compare cohorts of patients enrolled in the "Biobanque québécoise de la COVID-19" (BQC19) that experienced mild or severe COVID-19 or COVID-19-like symptoms attributed to another infectious agent. In Aim 3, we will focus on a cohort of health care worker tending COVID-19 patients, therefore at higher risk of repeat exposure to the virus. Using this cohort, we will study the effect of repeat exposure on immunity boosting against the virus and help define the immunological requirements of a successful vaccine. Taken together, our proposal will provide the immunological perspective needed to better prepare and implement a safe exit from the current public health crisis.
Department
Program
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Diagnostics
Location
Quebec, Canada
Recipient Type
Not-for-profit organization or charity
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
429272
Name
Kaufmann Daniel E
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Public Health Agency of Canada
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
COVID-19 Rapid Research - Diagnostics
Projecttitle
Early immune predictors of sustained SARS-CoV-2 antibody responses after COVID-19 disease
Programtype2
Operating Grants
Orgnameinp2
Centre hospitalier de l'Université de Montréal (CHUM)
Cihramount2
$0
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Diagnostics
Keyworddelim
Adaptive Immunity; Antibody Responses; Covid-19; Heath Care Workers; Immune Predictors Of Disease Risk; Innate Immunity; Personalized Medicine; Protective Antiviral Immune Responses; Sars-Cov-2; Systems Biology
Abstract
COVID-19, a disease caused by a new Coronavirus, is an unprecedented global health crisis for which we currently have nor safe nor rapid response. Given the absence of vaccines and effective therapies, it is essential to understand the development, effectiveness and maintenance of antiviral responses against its causing agent, the SARS-CoV-2 virus. The highly variable immune response against SARS-CoV-2 define the severity of the disease, but many critical questions remain: 1) can we predict patients that will experience a severe disease and delayed viral clearance? 2) do survivors of COVID-19 develop durable and protective antiviral immunity? 3) can serology identify convalescent COVID-19 patients who are at high risk of re-infection? 4) does re-exposure to the virus boost their antiviral immunity?
We propose the creation of a multi-site consortium composed of 12 scientists (6 women and 6 men) with solid expertise in virology and immunology and from leading academic institutions in Québec (UdeM, IRCM) and the US (Columbia, NY) to study antiviral immunity in COVID-19 in both sexes to address unresolved issues, as outlined in the CIHR call: in Aim 1 and 2, we focus on early clinical and immunological features of COVID-19 that can predict the emergence of protective and durable antibodies. We will compare cohorts of patients enrolled in the "Biobanque québécoise de la COVID-19" (BQC19) that experienced mild or severe COVID-19 or COVID-19-like symptoms attributed to another infectious agent. In Aim 3, we will focus on a cohort of health care worker tending COVID-19 patients, therefore at higher risk of repeat exposure to the virus. Using this cohort, we will study the effect of repeat exposure on immunity boosting against the virus and help define the immunological requirements of a successful vaccine. Taken together, our proposal will provide the immunological perspective needed to better prepare and implement a safe exit from the current public health crisis.
Competitiondate
202005
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kaufmann, Daniel E; Finzi, Andrés
Approvedterm
1 an 0 mois